Central Early-Stage Lung Cancer and a Pacemaker: Is SBRT Safe?
71-year-old man presents with a 2.6 cm right upper lobe squamous cell carcinoma. PET-CT shows no nodal or distant uptake. The tumor is central: its edge lies 1.2 cm from the trachea and 1.8 cm from the esophagus. He has a left prepectoral dual-chamber pacemaker implanted two years ago for sick sinus syndrome; the device is MRI-conditional and was last interrogated six months ago. Pulmonary function is FEV1 1.1 L (42% predicted) and DLCO 38% predicted. He uses home oxygen at night and has had two admissions for pneumonia in the past year. He is independent and wants the least disruptive treatment. The radiation oncologist must decide between sublobar resection, stereotactic body radiotherapy (SBRT), and conventionally fractionated radiotherapy, and must also address the pacemaker before simulation.
1. Is SBRT appropriate for this central tumor, and how do you weigh SBRT against sublobar resection and conventionally fractionated radiotherapy in a patient with FEV1 1.1 L and DLCO 38%?
Read the worked answer
This is a high-risk surgical patient: FEV1 1.1 L, DLCO 38%, home oxygen, and recurrent pneumonia. Sublobar resection is possible but carries substantial perioperative risk and may compromise pulmonary reserve. Conventionally fractionated radiotherapy (for example, 60–66 Gy in 30–33 fractions) is an option but is less ablative and requires many visits.
SBRT is reasonable even for a central tumor, provided normal-tissue constraints can be met. The older teaching that central tumors are absolutely unsuitable for SBRT came from high toxicity with very high single-fraction doses; modern five-fraction regimens for central tumors have acceptable toxicity in selected patients. The proximity to trachea and esophagus raises risks of stenosis, fistula, and esophagitis, so the plan must be judged on actual dose-volume constraints, not on the label “central” alone.
My recommendation: offer SBRT with a five-fraction schedule if the esophagus, trachea, spinal cord, brachial plexus, and pacemaker constraints are achievable. If not, use conventionally fractionated radiotherapy rather than forcing an unsafe SBRT plan. Discuss sublobar resection as an alternative but explain the pulmonary and perioperative risk.
2. If you proceed with SBRT, what dose/fractionation would you choose and which organs-at-risk constraints would drive the plan? Include the pacemaker in your physics planning.
Read the worked answer
I would choose a risk-adapted five-fraction SBRT regimen, commonly 50–55 Gy in five fractions for a central tumor, using daily image guidance and motion management. I would not use a single fraction or a three-fraction regimen near the trachea and esophagus.
Constraints that drive the plan (verify against the institutional protocol, as minor variations exist):
- Spinal cord: maximum dose ≤23 Gy and 0.1 cc ≤14 Gy for a five-fraction course.
- Esophagus: maximum dose ≤35 Gy and keep the hot spot small; higher doses risk stricture and fistula.
- Trachea: maximum dose ≤40 Gy; avoid circumferential high dose.
- Brachial plexus: maximum dose ≤30 Gy.
- Heart: keep dose as low as reasonably achievable, especially if the tumor abuts the mediastinum.
- Pacemaker: contour the generator and leads as an organ at risk. Keep the generator maximum dose below about 2 Gy and the lead dose as low as possible. Use 6 MV photons and avoid energies above 10 MV because neutron production can upset the device. Use cone-beam CT sparingly and coordinate with cardiology.
If these constraints cannot be met, I would convert to conventionally fractionated radiotherapy rather than accept a high-risk plan.
3. How would you manage the cardiac implantable electronic device before, during, and after treatment?
Read the worked answer
A pacemaker is at risk from cumulative radiation dose, neutron effects, and electromagnetic interference during imaging or treatment. Management is multidisciplinary.
Before treatment:
- Obtain a cardiology/electrophysiology assessment and device interrogation. Document battery status, lead function, pacing dependency, and whether the patient is pacemaker-dependent.
- Reprogram to an asynchronous mode or a mode that avoids inhibition if the patient is pacing-dependent, and disable antitachycardia therapies if an ICD were present.
- Provide a magnet and a plan for urgent device inhibition if needed.
During treatment:
- Use 6 MV photons; avoid high-energy beams that produce neutrons.
- Keep the generator out of the direct beam and monitor cumulative dose. Perform daily device checks if the patient is pacing-dependent, and keep ECG monitoring and resuscitation equipment available.
- Use image guidance judiciously; cone-beam CT can deliver dose to the device over many fractions.
After treatment:
- Interrogate the device at completion and again at follow-up. Look for battery depletion, reset, lead threshold changes, or arrhythmia logs. Advise the patient to report syncope, palpitations, or device alarms.